12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tosedostat: Interim Phase II data

Interim data from the first cohort of an open-label, U.S. Phase II trial in 26 patients ages >=60 years with newly diagnosed AML or high-risk MDS showed that once-daily 120 mg oral tosedostat on days 1-21 of a 35-day cycle plus either cytarabine or decitabine on days 1-5 led to a 4-month OS rate of 81%. There were 10 complete remissions and 4 complete remissions with incomplete blood count recovery. Ten patients subsequently received a hematopoietic stem cell transplantation (HSCT)....

Read the full 380 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >